Knowledge HQ

The authors developed a GMP-compliant TIL expansion protocol using G-Rex and the Xuri bioreactor. Pre-REP expansion in G-Rex resulted in higher cell numbers compared to 24-well plates. The closed-system process reduced operator time and produced functional TILs suitable for clinical trials.

The study demonstrates that blocking MICA/B shedding enables NK cells to target tumors with MHC-I or IFN-gamma pathway mutations. Human NK cells were expanded in vitro using G-Rex 6-well plates. This therapeutic strategy effectively reduced metastases in humanized mouse models.

This poster details the optimization of Treg expansion using Cloudz™ Treg CD3/CD28 microspheres. The method achieved high purity and cell numbers. Scalability was demonstrated using G-Rex6M plates, which utilize a gas-permeable membrane to support efficient cell growth in serum-free media.

This study explores nano-radiomics to assess response to MDSC-directed NK cell therapy in solid tumors. Human NK cells were activated and expanded in G-Rex devices for in vivo testing. Radiomic analysis of CT images successfully identified treatment responses that conventional tumor metrics failed to detect.

This study develops renewable artificial antigen presenting cells (aAPCs) for T cell expansion and transduction. Using G-Rex , aAPCs supported efficient production of CAR T cells and TILs with less exhaustion and higher potency than bead-based methods, offering a cost-effective manufacturing alternative.

The authors describe a GMP-compliant method to rapidly expand fungus-specific T cells using CD137 selection and short-term culture. G-Rex cell culture plates were used for the in vitro expansion of the enriched CD137+ population. The resulting T cells demonstrated potent antifungal activity against Aspergillus.

This study compares in-house produced CD19 CAR-T cells for ALL and NHL. Cells from ALL patients expanded better. Production utilized G-Rex100 , enabling rapid generation of therapeutic doses. The study highlights phenotypic differences based on the patient's disease.

The authors developed a scalable, serum-free process for lentiviral vector production using suspension-adapted SJ293TS cells. The vectors efficiently transduced human T cells and CD34+ cells. G-Rex plates were employed to expand the transduced T cells for assessing chimeric antigen receptor expression and titer.

This study compares monocyte-derived dendritic cell (Mo-DC) production in fluorinated ethylene propylene bags versus polystyrene plates. Mo-DCs generated in bags showed comparable phenotype and ability to activate T cells. G-Rex were utilized for the T cell co-culture steps to assess activation potency.

Evaluated TIL ACT for ovarian cancer. TILs were expanded using a 'TIL 3.0' method combining IL-2 with agonistic 4-1BB and anti-CD3 antibodies in G-Rex 10. This method significantly increased CD8+ TIL yield and success rates compared to IL-2 alone, producing tumor-reactive T cells in 2-3 weeks.

Study identifying E3L as a key antigen for protective T-cell immunity against vaccinia virus. Virus-specific T cells (VSTs) were generated, referencing previous protocols using G-Rex cultureware.

Study improving Vg9Vd2 T cell responses using NKG2D RNA CARs. Cells were expanded using K562 aAPCs in G-Rex vessels before electroporation. CAR-modified cells showed enhanced cytotoxicity against solid tumors in vitro and in vivo.